Nuvectis Orphan Status for Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

 Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that NXP800 was granted Orphan Drug Designation by the United States Food and Drug Administration (“FDA”) for the treatment of AT-rich interactive domain-containing protein 1a (ARID1a) ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

https://www.globenewswire.com/news-release/2024/08/29/2937745/0/en/Nuvectis-Pharma-Announces-Orphan-Drug-Designation-Granted-by-the-FDA-for-NXP800-for-the-Treatment-of-ARID1a-deficient-Ovarian-Fallopian-Tube-and-Primary-Peritoneal-Cancers.html